XML 19 R9.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Restructuring, Strategic Transaction and Integration (Notes) | 12 Months Ended
--- | ---
Dec. 31, 2019
Restructuring and Related Activities [Abstract] |
Restructuring and Related Activities Disclosure [Text Block] | RESTRUCTURING, STRATEGIC TRANSACTION AND INTEGRATION Restructuring and strategic transaction and integration expenses were $80.6 million, $105.4 million and $78.0 million for the years ended December 31, 2019, 2018 and 2017, respectively. Restructuring Restructuring charges were $8.4 million, $4.5 million and $18.8 million for the years ended December 31, 2019, 2018 and 2017, respectively, and are included in the above restructuring, strategic transaction and integration amounts on a separate line item in our consolidated statement of operations. During the year ended December 31, 2019, restructuring charges were primarily related to severance and facility closure costs. These charges were primarily related to a one-time charge to move our U.S. pump service depot to our existing Salt Lake City facility and other plant restructuring. The cumulative amount incurred to date in connection with the HIS acquisition is $25.1 million. In 2018 and 2017, we incurred restructuring charges related to the acquisition of the HIS business (see Note 2, Acquisitions). The restructuring charges were incurred as a result of integrating the acquired operations into our business and include severance costs related to involuntary employee terminations and facility exit costs related to the closure of the Dominican Republic manufacturing facilities acquired from Pfizer. In 2015, we incurred restructuring charges related to an agreement with Dr. Lopez, a member of our Board of Directors and a former employee in our research and development department, pursuant to which we bought out Dr. Lopez's right to employment under his then-existing employment agreement, the buy-out, including payroll taxes, will be paid in equal monthly installments until December 2020. The remaining payments owed are included in accrued liabilities in our consolidated balance sheet. The following table summarizes the activity for the restructuring-related charges discussed above and related accrual (in thousands):
| Accrued Balance January 1, 2018 |  | Charges incurred |  | Payments |  | Other Adjustments |  | Accrued Balance December 31, 2018 |  | Charges incurred |  | Payments |  | Other Adjustments |  | Accrued Balance December 31, 2019
Severance pay and benefits | $ | 915 |  |  | $ | 4,311 |  |  | $ | (4,549 | ) |  | $ | — |  |  | $ | 677 |  |  | $ | 5,634 |  |  | $ | (2,433 | ) |  | $ | — |  |  | $ | 3,878 |
Employment agreement buyout | 1,114 |  |  | — |  |  | (368 | ) |  | (7 | ) |  | 739 |  |  | — |  |  | (279 | ) |  | — |  |  | 460 |
Retention and facility closure expenses | — |  |  | 160 |  |  | (160 | ) |  | — |  |  | — |  |  | 2,741 |  |  | (1,530 | ) |  | — |  |  | 1,211 |
| $ | 2,029 |  |  | $ | 4,471 |  |  | $ | (5,077 | ) |  | $ | (7 | ) |  | $ | 1,416 |  |  | $ | 8,375 |  |  | $ | (4,242 | ) |  | $ | — |  |  | $ | 5,549 |
Strategic Transaction and Integration Expenses During the years ended December 31, 2019, 2018 and 2017, we incurred $72.2 million, $100.9 million and $59.2 million, respectively, in transaction and integration costs. These costs were primarily related to the acquisition and integration of HIS business, (see Note 2, Acquisitions). The integration expenses for the year ended December 31, 2019, included a one-time strategic supply chain restructuring charge of $22.1 million, which reduces our contracted commitments to our third party manufacturer and charges related to our Pfizer separation costs, which included a $12.7 million non-cash write-off of related assets.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -URI http://asc.fasb.org/topic&trid=2175745 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration